Collecting specimens and data for early detection and prevention of ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve strategies for the early detection and prevention of ovarian cancer, particularly among high-risk populations. It involves the collection of specimens and data to develop sensitive tumor markers and identify new prevention approaches. Participants will undergo periodic specimen collection, including blood and tissue samples, and may complete questionnaires to assess psychological functioning. The study focuses on understanding and managing ovarian cancer and related gynecological malignancies.

Why it matters

Who can join: the full rules

DISEASE CHARACTERISTICS:

* Meets one of the following criteria:

  * Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:

    * Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer
    * Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor
    * A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer
    * Increased risk as deemed by a certified genetic counselor
  * Undergoing surgery for a gynecologic condition, including any of the following:

    * Diagnosis of a reproductive cancer
    * Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)
    * Highly suspicious adnexal mass
    * Risk-reducing prophylactic oophorectomy

PATIENT CHARACTERISTICS:

Age

* Between the ages of 18 and 80

Where it's running

• Robert H. Lurie Comprehensive Cancer Center at Northwestern University
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Takelia Walker
• Email: takelia-watson@northwestern.edu
• Phone: 3125034802

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.